GlassScriptPhysician profile
Trinidad A Lim
NPI 1598716979
$3,750.51
in general payments reported to CMS, 2019-2025
25 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $507 · 2021: $577 · 2022: $201 · 2023: $279 · 2024: $702 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $23.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.43 |
| Education | $23.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $845.13 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $480.71 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $268.09 | 2023-2025 | |
| Akebia Therapeutics INC | $217.59 | 2019-2025 | Vafseo |
| Glaxosmithkline, LLC. | $207.67 | 2021 | |
| Opko Pharmaceuticals, LLC | $160.40 | 2019-2023 | Rayaldee |
| Baxter Healthcare | $134.87 | 2019-2020 | |
| Amgen INC. | $131.20 | 2019-2025 | Tavneos |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Aurinia Pharma U.S., INC. | $123.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $113.76 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $110.90 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $108.65 | 2024-2025 | Ibsrela |
| Outset Medical INC | $100.82 | 2024 | |
| Allergan, INC. | $96.52 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $92.72 | 2019 | |
| Medtronic Vascular, INC. | $83.84 | 2019 | |
| Calliditas Therapeutics US INC. | $79.99 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $54.18 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $46.47 | 2020-2024 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.87 | 2023-2025 | Jardiance |
| Amag Pharmaceuticals, INC. | $35.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.43 | 2024-2025 | |
| Amicus Therapeutics, INC. | $30.52 | 2019 | |
| Daiichi Sankyo INC. | $25.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinidad Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.